Nuo Therapeutics, Inc. (AURX) — 10-Q Filings

10-Q Filings (6)

• AURX Revenue Soars 128% Amidst Mounting Losses, Going Concern Doubt — Oct 30, 2025 Risk: high
  Nuo Therapeutics, Inc. (AURX) reported a significant increase in total revenue for the nine months ended September 30, 2025, reaching $2,216,679, up from $970,3
• Nuo Therapeutics' Losses Widen Amid Revenue Dip, New Stock Issuance — Jul 31, 2025 Risk: high
  Nuo Therapeutics, Inc. (AURX) reported a net loss of $1,057,000 for the six months ended June 30, 2025, a significant increase from the $652,000 net loss for th
• Nuo Therapeutics Files Q1 2025 10-Q — Apr 30, 2025 Risk: low
  Nuo Therapeutics, Inc. filed a 10-Q for the period ending March 31, 2025. The company, formerly known as CytomediX Inc. and Autologous Wound Therapy Inc., is in
• Nuo Therapeutics Files Q3 2024 10-Q — Nov 12, 2024 Risk: medium
  Nuo Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported financial results for the nine months and third quarter of
• Nuo Therapeutics Q2 2024: Assets $45.5M, Liabilities $44.2M — Aug 12, 2024 Risk: medium
  Nuo Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported total assets of $45,466,238 and total liabilities of $44,241,516
• Nuo Therapeutics, Inc. Files 10-Q for Period Ending March 31, 2024 — May 15, 2024 Risk: low
  Nuo Therapeutics, Inc. (AURX) filed a Quarterly Report (10-Q) with the SEC on May 15, 2024. Nuo Therapeutics, Inc. filed a 10-Q for the period ending March 31,

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX